Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination

NCT06690502 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1208

Last updated 2024-11-15

No results posted yet for this study

Summary

This study is Post Authorization Safety Study (PASS) Phase IV of Booster IndoVac COVID-19 Vaccination

Conditions

Sponsors & Collaborators

  • PT Bio Farma

    lead INDUSTRY

Principal Investigators

  • Hindra Irawan Satari, Prof., Dr., dr., SpA(K), M. Trop. Paed · National Committee of Adverse Events Following Immunization / NC Indonesia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-18
Primary Completion
2024-06-03
Completion
2024-06-07

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06690502 on ClinicalTrials.gov